Furthermore, pharmacologic blockade of TGF-β signaling leads to a reduction of GLI1 expression in cyclopamine-resistant pancreatic adenocarcinoma (Dennler et al., 2007). This evidence concerns the gene TGFB1 and pancreatic adenocarcinoma.